In Pursuit of Natural Product Leads: Synthesis and Biological Evaluation of 2-[3-hydroxy-2-[(3-hydroxypyridine-2-carbonyl)amino]phenyl]benzoxazole-4-carboxylic acid (A-33853) and Its Analogues: Discovery of N-(2-Benzoxazol-2-ylphenyl)benzamides as Novel Antileishmanial Chemotypes
- 7 November 2008
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 51 (23) , 7344-7347
Abstract
The first synthesis and biological evaluation of antibiotic 31 (A-33853) and its analogues are reported. Initial screening for inhibition of L. donovani, T. b. rhodesiense, T. cruzi, and P. falciparum cultures followed by determination of IC50 in L. donovani and cytotoxicity on L6 cells revealed 31 to be 3-fold more active than miltefosine, a known antileishmanial drug. Compounds 14, 15, and 25 selectively inhibited L. donovani at nanomolar concentrations and showed much lower cytotoxicity.Keywords
This publication has 16 references indexed in Scilit:
- Prodrugs for the Treatment of Neglected DiseasesMolecules, 2008
- Visceral leishmaniasis: what are the needs for diagnosis, treatment and control?Nature Reviews Microbiology, 2007
- Treatment options for visceral leishmaniasisExpert Review of Anti-infective Therapy, 2006
- Advances in leishmaniasisThe Lancet, 2005
- Oral Miltefosine for Leishmaniasis in Immunocompromised Patients: Compassionate Use in 39 Patients with HIV InfectionClinical Infectious Diseases, 2004
- Leishmaniasis: current situation and new perspectivesComparative Immunology, Microbiology and Infectious Diseases, 2004
- Characterization of pentamidine excretion in the isolated perfused rat kidneyJournal of Antimicrobial Chemotherapy, 2003
- Chemotherapy of LeishmaniasisCurrent Pharmaceutical Design, 2002
- Miltefosine — The Long-Awaited Therapy for Visceral Leishmaniasis?New England Journal of Medicine, 1999
- Human Leishmaniasis: Clinical, Diagnostic, and Chemotherapeutic Developments in the Last 10 YearsClinical Infectious Diseases, 1997